The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy

British Journal of Cancer

Volumn 79, Issue 9-10, 1999, Pages 1443-1447

  Nicolini, A ^a   Ferrari, P ^a   Sagripanti, A ^a   Carpi, A ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Bone metastases; Breast cancer; Equivocal bone scanning; Tumour markers

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; HEPATOGRAPHY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032976463     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690230     Document Type: Article

References (27)

1. ASCO Tumor Marker Expert Panel (1996) Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14: 2843-2877
2. Bonadonna G and Valagussa P (1993) Neoplasie della mammella. In Manuale di oncologia medica, Bonadonna G and Robustelli della Cuna G (eds), pp 529-563. Masson: Milano
3. Colman LK, Porter BA, Redmond J III, Olson DO, Stimac GK, Dunning DM and Friedl KE (1988) Early diagnosis of spinal metastases by CT and MR studies. J Comput Assist Tomogr 12: 423-426
4. Cuschieri A (1973) Urinary hydroxyproline excretion in early and advanced breast cancer - a sequential study. Brit J Surg 60: 800-803
5. Cushieri A (1977) Urinary hydroxyproline in the management of breast cancer. World J Surg 1: 299-302
6. Del Turco MR, Palli D, Cariddi A, Ciatto S, Pacini P and Distante V (1994) Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. JAMA 271: 1593-1597
7. Fatch-Moghadam A and Stieber P (1993) Use of tumour markers in certain solid tumours. In Sensible use of tumour markers, Fatch-Moghadam A, Stieber P (eds), pp 56-57. J Hartmann, Verlag GMBH: Munich
8. Fogelman I (1991) Bone scanning. In Clinical Nuclear Medicine, 2nd edn, Maisey MN. Britton KE and Gilday DL (eds), pp 131-157. Chapman and Hall Medical: London
9. Galasko CSB and Doyle FH (1972) The detection of skeletal metastases from mammary carcinoma. A regional comparison between radiology and scintigraphy. Clin Radiol 23: 295-297
10. Gielen F, Dequeker J, Drochmans A, Wildiers J and Merlevede M (1976) Relevance of hydroxyproline excretion to bone metaslasis in breast cancer. Br J Cancer 34: 279-285
11. Guzzo CE, Pachas WN, Pinals RS and Krant MJ (1969) Urinary hydroxyproline excretion in patients with cancer. Cancer 24: 382-387
12. Held P and Breit A (1994) Comparison of CT and MRI methods in diagnosis of tumours of the para- and retropharingeal space and temporal bone. Bildgebung 6: 263-271
13. Komaki R, Donegan W, Manoli R and Yeh EL (1979) Prognostic value of pretreatment bone scans in breast carcinoma. AJR 132: 877-881
14. Luthgens M, Schelegel G, Eklund G and Bjorklund B (1981) Correlation between activity in breast cancer and CEA, TPA and eighteen common laboratory procedures and the improvement by the combined use of CEA and TPA. Tumour Diagnostik 2: 6-11
15. Meissner W and Warren S (1971) Neoplasms. In Pathology, 6th edn. Mosby: St. Louis
16. Moulopulos LA, Dimopoulos MA, Smith TL, Weber DM, Delasalle KB, Libshitz HI and Alexanian R (1995) Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 13: 251-256
17. Mundy GR, Ibbotson KJ, D'Souza SM, Simpson EL, Jacobs JW and Martin TJ (1984) The hypercalcemia of cancer-clinical implications and pathogenic mechanisms. N Engl J Med 310: 1718-1722
18. Nicolini A, Carpi A, Di Marco G, Giuliani L, Giordani R and Palla S (1989) A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen and urinary hydroxyproline in breast cancer patients. Cancer 63: 2037-2046
19. Nicolini A, Colombini C, Luciani L, Carpi A and Giuliani L (1991) Evaluation of serum CA 15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 64: 154-158
20. Nicolini A, Carpi A and Tibaldi C (1992) The patients postoperative management of breast cancer patient: new concepts. In Progress in Clinical Oncology, Carpi A, Sagripanti A and Mittermayer CH (eds), pp 187-203. Sympomed Medical: Munchen
21. Nicolini A, Anselmi L, Michelassi C and Carpi A (1997) Prolonged survival by "early" salvage treatment of breast cancer patients: a retrospective six year study. Br J Cancer 76: 1106-1111
22. Robinson LA (1997) Radioisotope-guided surgical biopsy of suspected osseous metastases. Cancer Control 4: 517-522
23. Sanal SM, Flickinger FW, Caudell MJ and Sherry RM (1994) Detection of bone marrow involvement in breast cancer with magnetic resonance imaging. J Clin Oncol 12: 1415-1421
24. Shreve PD, Grossman HB, Gross MD and Wahl RL (1996) Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-(F-18) fluoro-D-glucose. Radiology 199: 751-756
25. Touitou Y, Proust J, Klinger E and Nakache JP (1985) Biological and pathological factors affecting plasma gamma-glutamyl transpeptidase and alkaline phosphatase activity in the elderly. Clin Chim Acta 146: 1-10
26. Virgo KS (1996) The costs of cancer patient follow-up post-treatment. In: ASCO Educational Book, pp 328-329, the American Society of Clinical Oncology: Place
27. White DR, Maloney JJ III, Muss HB, Vance RP, Barnes P, Howard V, Rhyne L and Cowan RJ (1979) Serum alkaline phosphatase determination-value in the staging of advanced breast cancer. JAMA 242: 1147-1149